Purpose of this Study
We are doing this study to find out if we can identify biomarkers that indicate the presence of ovarian cancer or indicate that it is likely to develop. Biomarkers are substances that can be released from cancer cells into the blood and can provide information on the following things: changes to someone's genes or DNA, how cancer cells will respond to cancer treatment, and whether cells are becoming resistant (no longer responding) to cancer treatment.
Who Can Participate?
Eligibility
Women ages 18+ who:
- Are scheduled to have a risk-reducing salpingo-oophorectomy procedure to remove their fallopian tubes or a removal of an adnexal (ovarian or fallopian tube mass) as part of their regular clinical care
- Have never been treated with chemotherapy or pelvic radiation
- Are not pregnant or breastfeeding
Age Range
18-110
Sex/Genders
Female (cisgender)
Looking for Healthy Participants
Yes
What is Involved?
Description
If you choose to join this study, we will collect the following samples from you:
- Blood draws
- Tissue samples from your fallopian tubes or an identifed mass on your fallopian tube(s) if you are scheduled to have them removed
Locations
Duke University Hospital
Duke Raleigh Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
Assessing the predictive capability of circulating tumor
DNA (ctDNA) as a screening tool for ovarian cancer
DNA (ctDNA) as a screening tool for ovarian cancer
Principal Investigator
Jennifer
McNally
Protocol Number
PRO00112908
Phase
Pilot
Enrollment Status
Open to Enrollment